Pharmaceuticals Sector - Solvay

Neopharma
On January 19, 2005 the Solvay group purchased 100% of the capital of Neopharma AG, a company active in
Sweden in pharmaceutical systems and preparations under the DUODOPA ® trademark for treating advanced stage
Parkinson’s disease. The net cash outlay was EUR 68 million.
The net assets acquired in the transaction and the resulting goodwill are:
EUR million Carrying
amount
before
acquisition
Fair value
adjustments
Intangible assets 95 95
Deferred tax assets 3 3
Non-current assets 0 98 98
Current assets other than cash and cash
equivalents
Total
1 1
Cash and cash equivalents 4 4
Current assets 5 0 5
Deferred tax liabilities 26 26
Non-current liabilities 0 26 26
Other current liabilities 5 5
Net assets 5 67 72
Total consideration paid 72
Bank balances and cash acquired -4
Net cash outlay on acquisition 68
Between January 19 and December 31, Neopharma, with its DUODOPA ® product at the launch stage, contributed
EUR 5 million to Group sales, with a negative EBIT of EUR 3 million due to restructuring charges and product launch
expenses.
Solvay Global Annual Report 2005
75